CELL INTELLIGENCE · 肿瘤细胞治疗研究

双靶向 MUC-1 和 PD-L1 的 CAR-NK92MI 联合免疫治疗用于复发/难治性实体瘤患者的 I 期试验：聚焦非小细胞肺癌

A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus

我们的结果表明，MUC-1 与 PD-L1 联合靶向的 CAR-NK92MI 细胞疗法是治疗伴转移的复发/难治性非小细胞肺癌患者的安全有效方法。

共同阻断 TIGIT 和 PVRIG 的新型双特异性抗体增强抗肿瘤免疫

Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity.

靶向 PD-1 和 CD85j 可恢复瘤内 CD4⁺ GzmB⁺ T 细胞功能以对抗表达 MHC-II 的肿瘤

Targeting PD-1 and CD85j can restore intratumoral CD4(+) GzmB(+) T-cell functions to combat MHC-II-expressing tumors.

我们的研究表明，肿瘤浸润性 CD4⁺GzmB⁺ T 细胞无法清除肿瘤。

更正：双靶向 PD-L1 和 MICA/B 的 CAR-NK 细胞在肺癌肿瘤模型中的作用

Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.

肺癌肿瘤模型中双靶向 PD-L1 和 MICA/B 的 CAR-NK 细胞

CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.

我们证实，dtCAR 的表达增强了 NK92 细胞在体外和体内的活化和杀伤能力，这为使用 NK 定制的 CAR 工程化 NK92 细胞治疗人肺癌提供了一种新的免疫治疗策略。

抗 CD47 抗体联合 CTLA4 阻断通过肿瘤血管正常化和免疫微环境重编程增强非小细胞肺癌的抗肿瘤免疫

The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vascul

靶向 MUC1 和 PSCA 的串联 CAR-T 细胞联合抗 PD-1 抗体对非小细胞肺癌表现出强效临床前活性

Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.

由 CAR-T 细胞来源外泌体与脂质体组成的序贯靶向杂合纳米囊泡用于增强肿瘤免疫化疗

Sequential Targeting Hybrid Nanovesicles Composed of Chimeric Antigen Receptor T-Cell-Derived Exosomes and Liposomes for Enhanced Cancer Immunochemoth

αVEGFR2-MICA 融合抗体增强免疫治疗效应并与 PD-1 阻断产生协同作用

αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.